Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Emmaus Life Sciences, Inc.

Get SEC filing alerts via email and in your feed for Emmaus Life Sciences, Inc.

EMMA

Emmaus Life Sciences, Inc.

About Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. Its primary product, Endari, is FDA-approved for sickle cell disease, reducing crises and hospitalizations. The company operates through licensing, distribution, and strategic partnerships, targeting global markets with a focus on innovative therapies, including cell sheet technology and cancer treatments, emphasizing safety, efficacy, and regulatory compliance.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Emmaus Life Sciences, Inc.

1
1
Emmaus Life Sciences, Inc. Emmaus Life Sciences Reports $1.98 Million Revenue Decline and $3.34 Million Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Emmaus Life Sciences, Inc. Emmaus Life Sciences Reports $7.2 Million Loss, Enters Distribution Agreement with NeoImmuneTech

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Emmaus Life Sciences, Inc. Emmaus Life Sciences Reports 38% Revenue Decline and Increased Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Emmaus Life Sciences, Inc. Emmaus Life Sciences Reports 48% Revenue Decline in Q2 2025 Amid Increased Competition

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Emmaus Life Sciences, Inc. Emmaus Life Sciences Reports $2.4 Million Revenue and $2.3 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Emmaus Life Sciences, Inc. Emmaus Life Sciences Reports Mixed Q3 Results, Net Loss, and Doubts About Future as a Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Emmaus Life Sciences, Inc. Emmaus Life Sciences Reports Significant Financial Challenges, Net Loss Widens Amid Inventory Shortage and Generic Competition

Via official filing (AI summary) | almost 2 years ago | 0 comments

8
1
Emmaus Life Sciences, Inc. Emmaus Life Sciences Reports Significant Financial Challenges, Net Loss Widens in Latest Quarter

Via official filing (AI summary) | almost 2 years ago | 0 comments